4195 — Genomics Bioscience & Technology Co Balance Sheet
0.000.00%
Last trade - 00:00- TWD1.37bn
- TWD1.87bn
- TWD708.38m
Annual balance sheet for Genomics Bioscience & Technology Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 119 | 329 | 265 | 261 | 199 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 83.2 | 100 | 117 | 139 | 184 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 252 | 498 | 472 | 615 | 639 |
| Net Property, Plant And Equipment | 311 | 373 | 499 | 648 | 648 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 853 | 1,120 | 1,134 | 1,360 | 1,426 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 94.6 | 169 | 146 | 383 | 533 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 174 | 331 | 368 | 812 | 916 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 679 | 789 | 766 | 549 | 510 |
| Total Liabilities & Shareholders' Equity | 853 | 1,120 | 1,134 | 1,360 | 1,426 |
| Total Common Shares Outstanding |